SCHEMBL18655504

SCHEMBL18655504

CCOc1cc2nc[nH]c(=O)c2cc1C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.50
CHEK1 O14757 2/20 0.50
PIM1 P11309 2/20 0.50
RPS6KA3 P51812 1/20 0.50
IP6K1 Q92551 3/20 0.43
ALDH1A1 P00352 1/20 0.43
AKT1 P31749 1/20 0.43
FLT3 P36888 1/20 0.43
PIM3 Q86V86 1/20 0.43
SRC P12931 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
SLC2A1 P11166 1/20 0.42
ACVR1 Q04771 2/20 0.40
IP6K3 Q96PC2 1/20 0.40
IP6K2 Q9UHH9 1/20 0.40
CYP1A2 P05177 1/20 0.40
TMIGD3 P0DMS9 1/20 0.40
CYP2C9 P11712 1/20 0.40
ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13090419 0.94 PARP1 (0.50) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL1011012 0.89 PARP1 (0.50) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL12247774 0.84 SRC (0.55) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL15960730 0.84 PARP1 (0.47) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL1014333 0.84 SRC (0.55) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL3240833 0.84 PARP1 (0.49) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL26112580 0.84 IP6K1 (0.50) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL1012421 0.84 SRC (0.55) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL31352893 0.84 IP6K1 (0.50) PARP1CHEK1PIM1RPS6KA3IP6K1
SCHEMBL14520678 0.81 IP6K1 (0.63) PARP1CHEK1PIM1RPS6KA3IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081293-A1 Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith WAKE FOREST UNIVERSITY 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081293-A1 Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PARP1 3817/4885CHEK1 58/4885PIM1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.